Anyone keeping tabs on Pfizer (NYSE: PFE) probably knows it still hasn’t rekindled its glory days early in the COVID-19 pandemic.
In 2022, it reported record-breaking revenue of just over $100 billion, largely thanks to sales of its COVID vaccine and treatment
Yet, last year’s top line was a stagnant $63 billion. On the other hand, anyone keeping a relatively close eye on this pharmaceutical giant also likely knows it’s been rebuilding its pipeline and portfolio, mostly through acquisitions like 2023’s $43 billion purchase of Seagen, which brought in the smaller company’s impressive oncology lineup. Still, there’s a problem.
True, Pfizer has several potential blockbuster drugs in development that could generate billions of dollars’ worth of annual revenue by 2030. But these investments won’t begin meaningfully paying off until 2028, with the anticipated launch of Pfizer’s own GLP-1 weight loss drug. That’s a long time for investors to wait on performance that isn’t exactly guaranteed.